



Carboplatin Now Available Through SICOR Agreement

Effective June 24, 2004, the following products have been added to the SICOR Agreement for OA Members:


- > Carboplatin Injection
- > Carboplatin for Injection
- > Fludarabine Phosphate Injection

SICOR is the first to market Carboplatin, the generic version of Paraplatin. Carboplatin is indicated for the treatment of advanced ovarian carcinoma of epithelial origin in: a) first line therapy; b) second line therapy, after other treatments have failed. Carboplatin is also indicated in the treatment of small cell carcinoma of the lung and in squamous cell carcinoma of the head and neck.

Fludarabine Phosphate Injection is the first ready-to-use solution format and is indicated for the treatment of patients with B-cell chronic lymphocytic leukemia who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. Ready-to use Fludarabine is available at no additional cost when compared to lyophilized Fludarabine.

For full prescribing information on Carboplatin and Fludarabine, visit www.newsicor.com. Contact OA at 888-732-7352 for any questions regarding the agreement.

NDC #	Product Description	Strength	Size	Package
00703-3244-11	Carboplatin Injection (Liquid Presentation)	50 mg	6 mL	1
00703-3264-01	Carboplatin for Injection (Lyophilized Presentation)	50 mg	6 mL	1
00703-3246-11	Carboplatin Injection (Liquid Presentation)	150 mg	20 mL	1
00703-3266-01	Carboplatin for Injection (Lyophilized Presentation)	150 mg	20 mL	1
00703-3248-11	Carboplatin Injection (Liquid Presentation)	450 mg	50 mL	1
00703-3268-01	Carboplatin for Injection (Lyophilized Presentation)	450 mg	50 mL	1
00703-4852-11	Fludarabine Phosphate Injection	50 mg	2 mL	1



GlaxoSmithKline Agreement Extended to Sept. 30, 2004

Oncology Associates is pleased to announce a new agreement extension for GlaxoSmithKline. Products on contract include: Hycamtin, Navelbine and Zofran Injection 20 ml vials and 32 mg premixed bags. The current OA contract has been extended from July 1, 2004 to September 30, 2004.

Zofran rebate checks for Q1, 2004 were released May 10, 2004. Rebates for Q2, 2004 will be released August 11, 2004.

To discuss any questions about the GlaxoSmithKline agreement or rebates, please contact OA at 888-732-7352.



Wyeth/Genetics Institute Contract Renewal for Neumega®

Oncology Associates is pleased to renew the following agreement for Neumega®, effective January 1, 2004. The contract provides discounted pricing for the product Neumega® in 5 mg vial and 5 mg vial 7/bx quantities.

Neumega® is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are high risk of severe thrombocytopenia.

Please contact Oncology Associates at 888-732-7352 for more information about the agreement for Neumega®.

NDC#	Vial Size	Vials per Box
58394-004-01	5 mg	1 vial; 1x10
58394-004-02	5 mg	1x7